BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 12, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Semuloparin: Phase III data

A meta-analysis of 3,457 evaluable patients undergoing major orthopedic surgery in the Phase III SAVE HIP 1, SAVE HIP 2 and SAVE KNEE trials showed that 20 mg once-daily semuloparin for 7-10 days after surgery significantly reduced the composite rate of any VTE...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >